OSLI Retina

October 2018

Issue link: http://osliretina.healio.com/i/1039004

Contents of this Issue

Navigation

Page 87 of 87

IMPORTANT SAFETY INFORMATION Contraindications DUREZOL® Emulsion, as with other ophthalmic corticosteroids, is contraindicated in most active viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures. Warnings and Precautions • Intraocular pressure (IOP) increase – Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. If this product is used for 10 days or longer, IOP should be monitored. • Cataracts – Use of corticosteroids may result in posterior subcapsular cataract formation. • Delayed healing – The use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation. In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical steroids. The initial prescription and renewal of the medication order beyond 28 days should be made by a physician only after examination of the patient with the aid of magnification such as slit lamp biomicroscopy and, where appropriate, fluorescein staining. • Bacterial infections – Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections. In acute purulent conditions, steroids may mask infection or enhance existing infection. If signs and symptoms fail to improve after 2 days, the patient should be re-evaluated. • Viral infections – Employment of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution. Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex). • Fungal infections – Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local steroid application. Fungus invasion must be considered in any persistent corneal ulceration where a steroid has been used or is in use. • Contact lens wear – DUREZOL® Emulsion should not be instilled while wearing contact lenses. Remove contact lenses prior to instillation of DUREZOL® Emulsion. The preservative in DUREZOL® Emulsion may be absorbed by soft contact lenses. Lenses may be reinserted after 10 minutes following administration of DUREZOL® Emulsion. Most Common Adverse Reactions • In postoperative ocular inflammation and pain studies, ocular adverse reactions occurring in 5-15% of subjects included corneal edema, ciliary and conjunctival hyperemia, eye pain, photophobia, posterior capsule opacification, anterior chamber cells, anterior chamber flare, conjunctival edema, and blepharitis. • In the endogenous anterior uveitis studies, the most common adverse reactions occurring in 5-10% of subjects included blurred vision, eye irritation, eye pain, headache, increased IOP, iritis, limbal and conjunctival hyperemia, punctate keratitis, and uveitis. For additional information about DUREZOL ® Emulsion, please see Brief Summary of Prescribing Information on adjacent page. * Limitations apply. For commercially insured patients. Up to a $155 cap per bottle. Patient will be responsible for any co-pay once limit per bottle is reached. This offer is not valid under Medicare, Medicaid, or any other federal or state program. Not valid for cash-paying patients. Novartis reserves the right to rescind, revoke, or amend this program without notice. Additional terms and conditions apply. Please see co-pay materials for details. Offer expires 12/31/18. References: 1. Durezol® [package insert]. Fort Worth, TX: Alcon Laboratories, Inc; 2017. 2. Stringer W, Bryant R. Dose uniformity of topical corticosteroid preparations: difluprednate ophthalmic emulsion 0.05% versus branded and generic prednisolone acetate ophthalmic suspension 1%. Clin Ophthalmol. 2010;4:1119-1124. 3. Korenfeld MS, Silverstein SM, Cooke DL, Vogel R, Crockett RS; Difluprednate Ophthalmic Emulsion 0.05% (Durezol) Study Group. Difluprednate ophthalmic emulsion 0.05% for postoperative inflammation and pain. J Cataract Refract Surg. 2009;35(1):26-34. 4. Fingertip Formulary, January 2018. INDICATIONS AND USAGE DUREZOL® (difluprednate ophthalmic emulsion) 0.05% is a topical corticosteroid that is indicated for: • The treatment of inflammation and pain associated with ocular surgery. • The treatment of endogenous anterior uveitis. Dosage and Administration • For the treatment of inflammation and pain associated with ocular surgery instill one drop into the conjunctival sac of the affected eye 4 times daily beginning 24 hours after surgery and continuing throughout the first 2 weeks of the postoperative period, followed by 2 times daily for a week and then a taper based on the response. • For the treatment of endogenous anterior uveitis, instill one drop into the conjunctival sac of the affected eye 4 times daily for 14 days followed by tapering as clinically indicated. INDICATIONS AND USAGE DUREZOL® (difluprednate ophthalmic emulsion) 0.05% is a topical corticosteroid that is indicated for: • The treatment of inflammation and pain associated with ocular surgery. • The treatment of endogenous anterior uveitis. Dosage and Administration • For the treatment of inflammation and pain associated with ocular surgery instill one drop into the conjunctival sac of the affected eye 4 times daily beginning 24 hours after surgery and continuing throughout the first 2 weeks of the postoperative period, followed by 2 times daily for a week and then a taper based on the response. • For the treatment of endogenous anterior uveitis, instill one drop into the conjunctival sac Novartis Pharmaceuticals Corporation East Hanover, New Jersey 07936-1080 T-DZL-1358097 © 2018 Novartis 6/18 Eligible commercial patients now pay as little as $ 30 * Explore the potency and proven efficacy of DUREZOL ® Emulsion at durezolhcp.com. + A potent and consistent formulation 1-3 + Excellent managed care coverage 4 • 90% commercial lives • 94% Medicare Part D lives Not actual patients. A POTE NT TH E R A PY FO R T H E T R E AT M E N T O F I N F L A M M AT I O N A N D PA I N FO LLOW I N G OCU L A R S U RG E RY

Articles in this issue

Links on this page

Archives of this issue

view archives of OSLI Retina - October 2018